|Awarded On||August 19, 2020|
|Title||CPRIT Early Clinical Investigator Award|
|Award Mechanism||Early Clinical Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||David Hsieh|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
Goal 1: Reduce mortality of patients with advanced hepatocellular carcinoma (HCC) by testing a novel strategy of increasing cancer immunogenicity to enhance the activity of immune checkpoint inhibitors. Objective 1: Assess the response rate (primary endpoint) of combining two clinical drugs with known safety profiles including a splicing modulator, E7820, and a checkpoint inhibitor, pembrolizumab, in a phase II trial in patients with advanced HCC. Objective 2: Assess the overall survival, progression free survival, duration of response, and safety (secondary endpoints) of combination immunotherapy. Goal 2: Develop pharmacodynamic markers and elucidate mechanisms of resistance to E7820 and...